Idiopathic Pulmonary Fibrosis

April 28, 2016May 31, 2016

Scientists Discover Shared Genes in COPD and IPF, Pointing to Potential Drug Development

COPD, Emphysema, Idiopathic Pulmonary Fibrosis, News

Despite sharing some risk factors, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) are usually studied in isolation, and the presence of possible shared molecular mechanisms has been unknown. Now, in a new study ... Read more

April 27, 2016April 28, 2016

New Insights into IPF Lung Disease Revealed with 3D Imaging Technique

Idiopathic Pulmonary Fibrosis, News

An advanced 3D X-ray imaging technique was applied for the first time to idiopathic pulmonary fibrosis (IPF) patients, providing new insight into how this aggressive disease develops in the body. The ... Read more

April 20, 2016April 20, 2016

Small Protein M10 Could Help Prevent Lung Fibrosis, According to Animal Study

Idiopathic Pulmonary Fibrosis, News, Scleroderma

A new study from researchers in South Carolina report that a small protein called M10 peptide might prevent fibrosis (scarring) in people with systemic sclerosis (SSc). M10 could be especially useful for ... Read more

April 13, 2016April 19, 2016

Phase 2a Clinical Trial for IPF Drug Launched by Galapagos

Idiopathic Pulmonary Fibrosis, News

Galapagos, a clinical-stage biotech that specializes in the discovery and development of small molecule medicines with novel modes of action, recently initiated an exploratory Phase 2a clinical trial (FLORA) with ... Read more

April 12, 2016April 19, 2016

Pulmonary Fibrosis Foundation Enrolls First Patient in Newly Launched National Registry

Idiopathic Pulmonary Fibrosis, News

The Pulmonary Fibrosis Foundation (PFF) enrolled the first patient in its new PFF Patient Registry, the foundation’s inaugural research tool that will comprise a broad collection of data from PF patients ... Read more

April 8, 2016April 8, 2016

Search for COPD, IPF and Asthma Treatments Could Benefit from Immune System Suppression Research

Asthma, COPD, Idiopathic Pulmonary Fibrosis, News

A collaborative study led by Weill Cornell Medicine investigators suggests that starving the immune system might lead to treatments for lung diseases, including chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), ... Read more

March 28, 2016April 4, 2016

Drug Company Collaboration for IPF Therapy Leads to Positive Results; Phase 1 Trial to Launch in 2017

Idiopathic Pulmonary Fibrosis, News

Synairgen recently announced positive results from its collaboration with Pharmaxis in their goal to develop a lysyl oxidase type 2 enzyme (LOXL2) inhibitor as an innovative treatment for the life-threatening lung disease ... Read more

March 22, 2016March 22, 2016

ProMetic’s Scleroderma Treatment PBI-4050 to Enter Phase 2 Clinical Trial

Idiopathic Pulmonary Fibrosis, News, Scleroderma

ProMetic Life Sciences recently announced the initiation of a Phase 2 clinical trial on PBI-4050 for the treatment of scleroderma, a chronic connective tissue disease for which there is currently ... Read more

March 18, 2016March 23, 2016

Study Finds IPF Patients Should Continue Pirfenidone Use Even as Disease Progresses

Idiopathic Pulmonary Fibrosis, News

An international group of researchers addressed an important clinical question about idiopathic pulmonary fibrosis (IPF) — Should people with IPF continue treatment with pirfenidone (Esbriet) if their disease meaningfully worsens? ... Read more

March 15, 2016March 16, 2016

For IPF Patients, Results Appear Promising in Phase 2 Study from FibroGen’s Investigative Drug

Idiopathic Pulmonary Fibrosis, News

FibroGen recently announced the publication of results from a Phase 2 clinical trial (NCT01262001) in patients with idiopathic pulmonary fibrosis (IPF), testing a 48-week treatment with the company’s investigational drug FG-3019, ... Read more